Home›Unlisted Shares›Pharmeasy (API) Unlisted Shares
Pharmeasy (API) Unlisted Shares

Pharmeasy (API) Unlisted Shares

₹6.560.00%
As on 11th Oct 2026 · market open
Industry: retailSector: pharmaDepository: NSDL, CDSL
DRHP Filed: No

Indicative price history

▼ ₹0.27(-3.95%)over 1 W

Indicative levels compiled by our team for information only — not a price feed, quote, or offer to deal.

52W Low ₹4.971Y Return +10.6%52W High ₹6.83
Key Indicators
Current Share Price
₹6.56
Unlisted market
Face Value / Share
₹1.00
Latest
Book Value / Share
₹4.90
Latest
Price to Earning (PE)
16.20
TTM basis
Price / Sales
0.60
TTM revenue
Price / Book
1.20
Book value basis
Outstanding Shares
702.56 Cr
Latest
Market Cap
₹4,208.35 Cr
At current price
Debt / Equity
0.90
Latest
Dividend / Share
₹0.00
Declared
Dividend %
0.00%
Yield
Return on Total Assets
-8.0%
RoA
Return on Equity
-15.1%
RoE
Working Capital Return
2.1%
RoWC
AboutFinancialsCorporate ProfileNews & BlogsFAQ

About Pharmeasy (API)

API Holdings Limited (Pharmeasy), as per its annual filings, is engaged in the business of undertaking and/or arranging or syndicating all types of business relating to the financing of industry or corporates like logistic and IT sectors. Further, during the year under review, the company had transferred its businesses of wholesale and distribution of drugs (including pharmaceutical products, medical devices, and OTC drugs) and ownership of technology and intellectual property for developing e-commerce platforms including marketplaces for facilitating the sale of pharmaceutical, medical devices, and OTC drugs to its wholly-owned subsidiaries through a slump sale on a going concern basis.
SectorRetail · Pharma
ISININE0DJ201029
Face Value₹1.0
DepositoryNSDL, CDSL
RTAlink intime
HQ902, 9th Floor, Raheja Plaza 1, B-Wing,Opposite R-City Mall, L.B.S Marg, Ghatkopar,Mumbai,400086

Financial Performance

Consolidated figures in ₹ Crore, from annual reports and public filings.

Indicators2026202520242023202220212020
Revenue6,689.35,980.05,758.96,699.75,781.02,360.7737.4
Expense6,580.56,533.56,311.08,065.18,074.52,904.61,053.7
EBITDA108.8-553.4-552.1-1,365.4-2,345.7-543.9-316.3
Other Cost564.9963.41,969.83,831.2-843.876.330.7
PBT-456.1-1,516.9-2,521.9-5,196.6-3,971.4-620.3-347.0
Tax Expense64.255.511.515.221.721.1-11.7
PAT-520.3-1,572.4-2,533.4-5,211.8-3,993.2-641.3-335.3
Other Inc./Exp.1.60.02.39.2-34.55.10.1
Net Income-518.7-1,572.4-2,531.1-5,202.6-4,027.7-636.3-335.2
Shares O/S702.561,703.30624.00614.20553.10238.70238.70
EPS (₹)0.37-1.05-4.10-8.50-7.30-2.70-1.50
Rev. Growth %11.9%3.8%-14.0%15.9%144.9%220.1%—
EBITDA Mgn %1.6%-9.3%-9.6%-20.4%-40.6%-23.0%-42.9%
Net Mgn %-7.8%-26.3%-44.0%-77.7%-69.7%-27.0%-45.5%
EPS Growth-135.2%-74.4%-51.8%16.4%170.4%80.0%—

Financials are as published on stockify.net.in and compiled from public filings. Refer to the audited annual report for exact figures.

Corporate Profile

Registered details, management and downloadable documents.

ISININE0DJ201029
PANAASCA1201E
Address902, 9th Floor, Raheja Plaza 1, B-Wing,Opposite R-City Mall, L.B.S Marg, Ghatkopar,Mumbai,400086
RTAlink intime

News & Press Release

View All →

Frequently Asked Questions

How to buy unlisted shares of API Holdings Ltd(PharmEasy)?+
Due to past performance and potential to grow, investment in API Holdings Ltd(PharmEasy) unlisted shares is a wise choice. At Stockify, you can easily buy and sell unlisted shares of API Holdings Ltd(PharmEasy). You just need to connect with our expert share brokers, and they will help you throughout the process.
How to Sell unlisted shares of API Holdings Ltd(PharmEasy)?+
If you are wondering how to sell API Holdings Ltd(PharmEasy) shares online, just fill out basic details in the form and our experts will get back to you. Right from the initial deal to the final transfer of shares, our unlisted share brokers will help. Check out the list of the best unlisted shares in India or reach out to reputed unlisted share dealers online.
What is the lock-in period of API Holdings Ltd(PharmEasy) unlisted shares?+
SEBI has recently reduced the lock-in period from 1 year to 6 months. There is a minimum lock-in period of 6 months from the date of purchase of unlisted shares. However, these shares can be freely transferable before listing in NSE/BSE. Connect with unlisted share experts at +91-80 4113 3935/+91-7353266646
What is the minimum ticket size for investment in API Holdings Ltd(PharmEasy) unlisted shares?+
In the recent, unlisted share market in India is spreading its wings and becoming quite big. Some highly recognized companies like Reliance, HDB finance and even the National Stock Exchange are trading unlisted stocks. At Stockify, we allow you to buy and sell any number of API Holdings Ltd(PharmEasy) unlisted shares as per your budget or needs. Customise your unlisted share trading experience.
Is it legal to buy unlisted shares of API Holdings Ltd(PharmEasy) in India?+
Yes, this is 100% legal and safe to buy unlisted shares of API Holdings Ltd(PharmEasy). However, this is applicable when you buy API Holdings Ltd(PharmEasy) unlisted shares from reliable and known unlisted share dealers. You can request a quote or trade online at Stockify, we are ready to assist you.
Is Short-term capital gain tax applicable on API Holdings Ltd(PharmEasy) unlisted shares?+
There is no difference between the tax of unlisted and listed shares. Short-term capital gain taxes are usually paid on the profit of shares held for one year or less. A rate of 15% will be charged as STCG tax and surcharges will be added based on the period of your holding. Buying unlisted shares in bulk? Talk to our experts to learn more.
Is there any Long-term capital gain tax to be paid on API Holdings Ltd(PharmEasy) unlisted shares?+
Yes, long term capital gain tax applies on unlisted shares. LTCG applies on shares held for more than a year. Long term capital gains might vary between 0 percent, 15 to 20 percent based on the duration of holding and income on share. Consult with our qualified unlisted share brokers in India to pick the most profitable unlisted stocks.
Applicability of Taxes on API Holdings Ltd(PharmEasy) unlisted shares once it is listed?+
There is no difference between the tax of unlisted and listed shares. Tax liability depends on the holding period of shares, not on the listing of shares in the stock exchange.
How to check the credit or transfers of API Holdings Ltd(PharmEasy) unlisted shares?+
The credit transfer process is also the same for both listed and unlisted stocks. Once the share is transferred it will be reflected in your depositary/Demat account NSDL/CDSL. You can also check it online by logging into the NSDL/CDSL account.
What is the documentation requirement for dealing in unlisted shares?+
At Stockify, we have simplified the whole process of unlisted share trading. A basic KYC is required for investing in unlisted stocks. For KYC verification, you will need to show Adhar | PAN | Demat CML For NRI |PAN|DEMAT CML| NRO Bank statement. Want to know more about how to buy unlisted shares in India? Connect with expert share brokers today!
What are expected returns on unlisted shares of API Holdings Ltd(PharmEasy) shares?+
There are multiple factors such as Demand/Supply of shares, valuation of the companies & multiple other factors that affect the returns on any unlisted shares. For eg. Investment of 1 Lakh in CSK shares in 2019 is worth 20 lakhs today in 2022 (20x returns in just 3 year). The return on investment of unlisted shares also varies depending on the period of holding. Estimating a return on unlisted shares requires in-depth knowledge and understanding of the industry. So, you can connect with our unlisted share experts to get a greater share of profit
Is the trading of PharmEasy unlisted shares legal in India?+
Yes, selling and buying PharmEasy unlisted shares is ethical and legal in India. If you are interested in purchasing, connect with the experts at Stockify today, consult the best options for your portfolio and simply buy them with us for hassle-free trading!
Is DIS used while selling PharmEasy unlisted shares?+
Yes, both online and offline DIS is available for PharmEasy unlisted shares. Since Stockify is an online unlisted shares broker, you can simply fill out the online DIS for PharmEasy unlisted shares.
Where should I buy PharmEasy unlisted shares from?+
You can buy PharmEasy unlisted shares easily from Stockify. Check out the PharmEasy share price today, consult our experts, spot your requirements and hit “buy”!
Who is the parent company of PharmEasy?+
The parent company of PharmEasy is API Holdings Limited. Founded in 2015 by Dharmil Sheth and Dr. Dhaval Shah, PharmEasy operates under this parent company, which oversees its various healthcare services, including online medicine delivery, diagnostic tests, and teleconsultation services.
Who is the promoter of PharmEasy?+
The promoters of PharmEasy are Dharmil Sheth, Hardik Dedhia, and Dr. Dhaval Shah. They co-founded the company in 2015. The parent company, API Holdings Limited, oversees PharmEasy's operations and strategic direction.
Who is the CEO of PharmEasy?+
The CEO of PharmEasy is Siddharth Shah. He is also a co-founder of the company.
Who is PharmEasy backed by?+
PharmEasy is backed by Manipal Education and Medical Group (MEMG). Other notable investors include Prosus, Temasek, 360 One Portfolios, CDPQ Private Equity, WSSS Investments, Goldman Sachs, and Evolution Debt Capital.
Is PharmEasy listed in stock market?+
PharmEasy is currently not listed on the stock market. Although its parent company, API Holdings, had filed for an initial public offering (IPO) in November 2021, the listing has been postponed multiple times due to challenging market conditions.

About PharmEasy Unlisted Shares (API Holdings Ltd.)

What kind of company is PharmEasy?

India’s digital consumer healthcare app, PharmEasy is referred to as a super app, offering customers on-demand access to home delivery for a comprehensive range of prescriptions and OTC pharmaceuticals. The company provides consumer healthcare products, information, consultations, and diagnostics tests from renowned laboratories. The company has collaborated with trusted doctors and registered in-store pharmacies. Incorporated in 2015, PharmEasy currently has over 2 million registered users and 17 million monthly active users. Moreover, with a market capitalization of approximately ₹5307 crores, PharmEasy unlisted shares are presently a whizz among investors and financial advisors.

Established by Dharmil Seth and Dr Dhaval Shah, PharmEasy serves every habitable zip code. The authorized share capital of the company is Rs. 1031.08 Cr and the total paid-up capital is Rs. 619.69 Cr. The initial idea of the company was to give end users an online pharmacy, but with the inclusion of consultation from trusted doctors and diagnostic tests from renowned laboratories, the application turned out to be quintessential. Furthermore, the company closed a revenue of Rs 56,642 Million in the fiscal year 2024 as opposed to Rs.66,997 Million in FY2023.

Financial Analysis of Pharmeasy Unlisted Shares

Particular (in Rs Cr)

2025

2024

2023

Revenue

5,980

5,758.90

6,699.70

EBITDA

-553.4

-552.1

-1,365.40

PAT (Net loss)

-1,572.40

-2,533.40

-5,211.80

Net Margin

-26.30%

-44%

-77.70%

Cash

119

327.9

193.6

Total Assets

6,976.60

8,389.60

8,256.40

Total Equity

3,272.30

2,588.40

2,436.90

Debt Level

3,704.30

5,801.20

5,819.50

EPS

-1.05

-4.1

-8.5

Revenue declined sharply from Rs 6,699.7 crore in FY23 to Rs 5,758.9 crore in FY24, reflecting a contraction of nearly 14%. This decline raised concerns around market share retention, competitive pricing pressure and consumer demand volatility in the online pharmacy sector.

In FY25, revenue recovered slightly to Rs 5,980 crore, but it remains well below peak levels, showing that the business has not fully regained momentum.

Despite weak revenue growth, losses have reduced significantly. Net loss improved from Rs 5,211.8 crore in FY23 to Rs 2,533.4 crore in FY24 and Rs 1,572.4 crore in FY25, reflecting aggressive cost controls and restructuring efforts. 

EBITDA losses have also narrowed, from Rs 1,365.4 crore in FY23 to Rs 552.1 crore in FY24 and Rs 553.4 crore in FY25. But margins remain negative, meaning the company has not yet found a sustainable profit model. The persistent negative EBITDA shows ongoing pressure on unit economics, high customer acquisition and servicing costs and limited scale-based operating leverage.

Until EBITDA moves into stable positive territory, valuation expansion remains difficult.

However, despite this progress, the losses remain too large to support sustainable shareholder value creation. Multiple years of negative EPS, from -8.5 in FY23 to -1.05 in FY25, indicate erosion of investor returns, contributing to ongoing pressure on API Holdings’ share price in the unlisted market.

Overall, the gradual improvement in losses is encouraging, but profitability, liquidity and scale remain critical challenges. Until the company demonstrates consistent positive cash flow, the unlisted share price is likely to stay under pressure.

Why Buy PharmEasy Unlisted Shares?

PharmEasy emerged as the most prominent name in the industry after its merger in 2020. With API Holdings as the parent company, PharmEasy is determined to show a staging growth rate, and investors are anticipating nothing less from the firm. Its parent company witnessed a total income that was more than doubled to $714 million in the fiscal year 2022. Though the PharmEasy stock price witnessed a low in the last few months, the data below clearly depicts that investors are not ready to sell their PharmEasy unlisted shares, further indicating their belief in the growth.

Pharmeasy Share 2026 Plans

From August 25, Rahul Guha has taken charge as the MD & CEO of Pharmeasy. Setting ambitious plans for FY 26-27, including full-year EBITDA profitability and PAT positivity by March 2027.

“Our overall vision is to build India’s best digital health platform,” Guha told Moneycontrol in an interview. “But my first priority is to get the group back on a profitability path.”

How To Apply For PharmEasy Unlisted Shares Online?

Buying PharmEasy unlisted shares is pretty easy, especially with Stockify. We are here with an ensemble of details such as Key Performance Indicators, revenue growth, EBITDA margin reports, EPS growth, etc. Moreover, the expert stockbrokers at Stockify constantly keep track of the trends and changes in the PharmEasy unlisted shares price and update prices as per the market fluctuation daily.

PharmEasy stock price is currently the talk of the town. Analyse and compare the key indicators, figure out your requirements and rely on our experts to guide you throughout the PharmEasy unlisted shares buying process. We will take care of everything – from guidance to documentation.

Check PharmEasy Unlisted Share Price at Stockify

The PharmEasy company share price is updated every day at Stockify. Our experts stay updated with stock market trends and keep a close eye on PharmEasy stock price fluctuations and immediately update prices as per the market trends on a daily basis. If you are interested in buying PharEasy Unlisted Shares, connect with us and stay tuned to our prices.

You can subscribe to our newsletter to get regular updates regarding PharmEasy share price, market trends, and other indicators that assist in determining whether or not a share is beneficial for your portfolio.

Check Out Prices Of Other Unlisted Shares On Stockify

For those who want to cope with market fluctuation, portfolio diversification is paramount for them. Diversification is a vital way to minimise the blow that hits while the market goes down. Stockify brings a list of unlisted shares from top-rated Pre-IPO companies at authentic prices. Apart from buying and selling PharmEasy unlisted shares, you can also check the best unlisted shares in India. We bring you unlisted shares from all the sectors – IT, energy, healthcare, insurance, technology, finance, manufacturing, and many more. Take a look at the PharmEasy share price and also glance up other unlisted shares hosted by Stockify.

Login To Buy PharmEasy Unlisted Shares!

Pharmeasy (API) · Unlisted
₹6.56